| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1097 | 2015 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1097 | 2015 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 556 | 2017 |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 407 | 2016 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 335 | 2019 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... Cancer discovery 6 (1), 36-44, 2016 | 297 | 2016 |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 281 | 2015 |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 204 | 2016 |
| Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018 | 137 | 2018 |
| Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ... Cancer research 76 (15), 4504-4515, 2016 | 115 | 2016 |
| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ... Nature Medicine 28 (8), 1612-1618, 2022 | 105 | 2022 |
| Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor F Orzan, F De Bacco, G Crisafulli, S Pellegatta, B Mussolin, G Siravegna, ... Stem cells 35 (11), 2218-2228, 2017 | 61 | 2017 |
| Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO 3 fusions G Picco, C Petti, A Centonze, E Torchiaro, G Crisafulli, L Novara, ... EMBO molecular medicine 9 (3), 293-303, 2017 | 60 | 2017 |
| Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases G Siravegna, E Geuna, B Mussolin, G Crisafulli, A Bartolini, D Galizia, ... Esmo Open 2 (4), e000253, 2017 | 60 | 2017 |
| Liquid biopsies to monitor and direct cancer treatment in colorectal cancer G Mauri, PP Vitiello, A Sogari, G Crisafulli, A Sartore-Bianchi, S Marsoni, ... British Journal of Cancer 127 (3), 394-407, 2022 | 56 | 2022 |
| Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ... Cancer Discovery 12 (7), 1656-1675, 2022 | 56 | 2022 |
| Werner helicase is a synthetic-lethal vulnerability in mismatch repair–deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy G Picco, CM Cattaneo, EJ van Vliet, G Crisafulli, G Rospo, S Consonni, ... Cancer discovery 11 (8), 1923-1937, 2021 | 56 | 2021 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016; 6: 36–44. doi: 10.1158/2159-8290 M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... CD-15-0940.[Abstract][CrossRef][Google Scholar], 0 | 44 | |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016; 6: 147–153. doi: 10.1158/2159-8290 M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... CD-15-1283.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 44 | |
| Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor G Siravegna, A Sartore-Bianchi, B Mussolin, A Cassingena, A Amatu, ... Annals of Oncology 28 (6), 1302-1308, 2017 | 38 | 2017 |
Federica Di NicolantonioUniversity of Torino, Dept of Oncology & Candiolo Cancer Institute, FPO - IRCCSVerified email at unito.it
